CMS's 2027 Rebate Reallocation Rule Drives MA-PD Part D Premiums to Zero

Medicare Advantage prescription drug plans that bid below their county benchmark collect a rebate worth 50% to 70% of that gap, and CMS's late-July 2026 guidance now requires every rebate dollar routed to Part D to drive the plan's total drug premium to exactly zero, absorbing the surplus through a richer supplemental benefit or an offsetting premium (CMS, July 2026).

How a Bid Below Benchmark Becomes a Rebate Check

Every Medicare Advantage plan submits a bid each June estimating the cost of covering Part A and Part B benefits for a standard enrollee, a deadline the CY2027 bid cycle kept on its usual first-Monday-in-June schedule (Axene Health Partners, 2026). CMS compares that bid to a statutory county-level benchmark, and when the bid lands below it, the difference becomes a rebate the sponsor is legally required to spend on enrollees rather than keep as pure margin. The share of that gap a plan actually gets to spend depends on its star rating: 70% for plans rated 4.5 stars and above, 65% for plans between 3.5 and 4.5 stars, and 50% for plans below 3.5 stars (KFF, August 2026). A five-star plan that bids $50 below its benchmark keeps $35 of that gap as spendable rebate; an otherwise identical three-star plan keeps $25 on the same $50 spread. Sponsors must spend every rebate dollar on one of four channels: buying down the Part B premium, cutting cost sharing, funding supplemental benefits such as dental and vision, or subsidizing the Part D drug benefit bundled into the MA-PD product.

That fourth channel is where the 2027 rule lands. In 2026, MA-PD sponsors directed roughly $600 per enrollee per year, or just over $50 per member per month, of their rebate pool into Part D premium buydowns and supplemental drug coverage, out of about $2,400 in total rebate dollars generated per enrollee across all four channels (KFF, 2026). That 26% Part D allocation is what funds the near-zero drug premiums MA-PD carriers advertise every Annual Enrollment: 79% of individual MA-PD enrollees paid no Part D premium at all in 2026, against 28% of standalone prescription drug plan (PDP) enrollees, and the average MA-PD Part D premium ran about $8 a month against $36 to $44 for a standalone PDP (KFF, 2026). Nationally, MA rebate dollars financed roughly $13 billion of Part D coverage in 2026, about 3.5 times the $3.6 billion the standalone Premium Stabilization Demonstration cost over the same stretch (KFF, 2026).

The $0 Total Part D Premium Rule and the Enhanced Alternative Trade

CMS's guidance changes what happens once a plan's own Part D bid pricing tool produces a negative basic premium, meaning rebate dollars assigned to Part D more than offset the basic premium the plan would otherwise charge. A below-zero premium is not a product CMS will publish, so rather than let that surplus sit as banked sponsor margin, the rule forces it to convert into member-facing benefit. Sponsors reach a $0 total Part D premium one of two ways: raise the Part D supplemental premium enough to absorb the negative basic premium on a bid that already carries an enhanced alternative (EA) benefit, or add an EA benefit with a new supplemental premium sufficient to soak up the difference on a bid that does not yet have one. CMS's Office of the Actuary walked plan actuaries through the mechanics on a May 14, 2026, Actuarial User Group call led by Jennifer Lazio, FSA, MAAA, director of the Parts C & D Actuarial Group, including a provision that a sponsor can satisfy the zero-premium requirement by enhancing the benefit to at least 70% of the Defined Standard Out-of-Pocket-Cost threshold (CMS Office of the Actuary, May 2026). Basic PDPs and Puerto Rico Platino plans that have no EA conversion option may instead absorb the surplus into gain/loss margin without touching benefit design, the one carve-out where the rule still permits the dollars to disappear into the sponsor's own books.

What sponsors cannot do during the reallocation window is touch the underlying pricing or design of the Part D basic benefit or the EA supplemental benefit itself; that scope locks at the original June bid submission. Rebate reallocation is a premium-and-margin exercise layered on top of a bid that is otherwise frozen, not a re-underwriting exercise. All Part D plans had until 11:59 p.m. Pacific on August 6, 2026, to complete reallocation and lock the numbers that feed CMS's September landscape file (CMS, July 2026).

	MA-PD (2026)	Standalone PDP (2026)
Average Part D premium	~$8/month	$36-$44/month
Share paying $0 Part D premium	79%	28%
Rebate dollars available for Part D	~$600/enrollee/year	None; no medical bid to draw from
Federal support beyond standard subsidy	$13B in MA rebates directed to Part D	$3.6B stabilization demo (ends Dec. 31, 2026)

Source: KFF, 2026.

Why the 24% Bid Jump Redirects Rebate Dollars Toward Drug Coverage

The CY2027 national average monthly bid amount of $296.05 is a 24% increase over 2026 and more than 750% above the $34.71 NAMBA recorded in 2023, the last full year before the Inflation Reduction Act's redesigned Part D benefit took effect (CMS, July 2026; Avalere Health, July 2026). The redesign eliminated the coverage gap, capped the annual out-of-pocket maximum at $2,000 for 2025 (rising to $2,400 proposed for 2027), and shifted manufacturer discount obligations into the initial and catastrophic phases, all of which raised the cost basis loaded into every Part D bid, standalone or bundled into an MA-PD product. A larger basic Part D bid widens the gap between that bid and whatever rebate-funded offset an MA-PD sponsor can bring to bear, which is exactly the arithmetic that produces more negative-premium scenarios for plans with strong medical-side bids and high star ratings. The 2027 rebate-reallocation guidance is CMS closing the gap a rising Part D cost basis, met by an unchanged or growing rebate pool, would otherwise open: instead of a sponsor banking a below-zero Part D premium as pure margin, the rule requires that value to convert into a member-facing benefit, either lower cost sharing on drugs already covered or genuinely enhanced coverage layered on top.

The Margin Trade-Off Behind the Zero-Premium Mandate

That statutory intent runs directly into a Medicare Advantage cost environment with little room to give. Wakely Consulting Group's analysis for AHIP of the CY2027 rate notice found the broader pool of rebate dollars MA plans can spend on premium buydowns, out-of-pocket protection and supplemental benefits could shrink by 15%, with dental and vision coverage potentially cut by half and premiums rising by an average of $23 a month across the book (Becker's Payer Issues, 2026, citing Wakely for AHIP). actuary.info's tracking of CY2027 bid filings has already shown sponsors trimming medical-side extras and, in some counties, exiting the market entirely as benchmark growth flattens (see "CY2027 MA Bids Lock In as Actuaries Navigate Tighter Margins"). The rebate-reallocation rule adds a second, non-negotiable claim on that same shrinking pool: rebate dollars a sponsor might otherwise have preferred to hold as margin, or redirect toward a grocery allowance or an over-the-counter card, now carry a mandatory first call to zero out Part D. A plan actuary building the 2027 bid strategy is not choosing between richer supplemental benefits and protecting margin in the abstract; the choice narrows to which supplemental line gets funded, medical or pharmacy, because pharmacy now carries a compliance floor the medical side does not.

Standalone PDPs Don't Get the Rebate Lever, and the Low-Income Benchmark Diverges

Standalone PDPs cannot borrow this way. A stand-alone plan's entire premium comes out of its own Part D bid; there is no adjoining medical bid throwing off rebate dollars to draw on, and the demonstration that shielded standalone premiums for two years, the Part D Premium Stabilization Demonstration, ends December 31, 2026 (see "CMS 2027 Part D Preliminary Bid: The Stabilization Demo Ends"). The same $296.05 national average bid that MA-PD sponsors can partially absorb with rebate dollars lands on standalone PDP pricing with no offset at all, which is the structural reason two products priced against an identical NAMBA produce such different premium outcomes: roughly $8 a month on the MA-PD side against $36 to $44 for a standalone PDP in 2026, a gap set to widen further once the demo's cushion disappears for 2027.

The low-income subsidy (LIS) benchmark complicates the comparison further. Beneficiaries who qualify for the subsidy pay no premium as long as their plan's premium sits at or below their region's benchmark, a figure calculated separately for the PDP and MA-PD segments and weighted toward each segment's own enrollment and bid mix. Because MA-PD premiums are already compressed toward zero by rebate dollars, and now further compressed by the 2027 zeroing rule, a larger share of MA-PD offerings clear the regional LIS benchmark automatically, while standalone PDPs, facing the unsubsidized post-demonstration bid, are more likely to land above it. That asymmetry feeds directly into where CMS auto-assigns or re-assigns LIS beneficiaries at the start of the plan year, concentrating low-income lives further into the MA-PD channel relative to the standalone market, a mix shift that itself becomes an input into how both segments price their CY2028 bids.

What Shows Up in the September Landscape File

CMS finalizes plan-specific premiums and benefit detail in the September 2026 landscape release ahead of the October 15 open enrollment start. Between the August 6 rebate-reallocation deadline and that release, the practical output of the rule shows up in three places a pricing or reserving actuary can already model against. First, the specific supplemental drug benefits, lower deductibles, richer tiering, $0 cost sharing on additional drug classes, that MA-PD plans add to satisfy the EA requirement, rather than simply banking the negative premium. Second, the plans that instead raise a Part D supplemental premium rather than enhance the benefit, a path CMS's guidance explicitly allows and one that will show up as a line item most enrollees will not notice sitting next to a $0 headline premium. Third, county-level competitiveness: a sponsor already trimming medical-side extras under benchmark pressure now has a second, mandatory draw on the same rebate pool for the drug benefit, which narrows how much room is left to compete on the medical-side supplemental package that has historically differentiated MA-PD bids at the county level.

The 24% NAMBA jump widened the negative-premium scenario at the pricing-cell level; the rebate-reallocation rule forces every dollar of that scenario into a member-facing benefit rather than sponsor margin, which is the opposite of what a plan under medical-side cost pressure would otherwise choose to do with a rebate windfall. Reserving and pricing teams building 2027 Part D assumptions now have a second constraint layered on top of the basic benefit cost trend: not just what the redesigned benefit costs to cover, but which of two mandatory absorption paths, supplemental premium or enhanced benefit, a given bid cell has to take to reach zero.